Topics:
Breast Cancer • Radiation Oncology • Medical Oncology • Breast Cancer, Metastatic • Breast Cancer, Non-metastatic
What are your top takeaways from SABCS 2023?
Answer from: Radiation Oncologist at Academic Institution
The B51 trial surprised the radiation oncology community, showing that in patients with an exceptional response to systemic therapy, radiation to the regional nodes did not result in a significant improvement in the invasive breast cancer recurrence free interval nor the isolated loco-regional rec...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
INAVO120 study: The study looked at triplet therapy using inavolisib (PIK3CA inhibitor) plus palbociclib and fulvestrant vs. palbociclib and fulvestrant in women with metastatic ER+HER2- breast cancer that has recurred while on or within 12 months of adjuvant endocrine therapy. The progression fre...
Answer from: Medical Oncologist at Academic Institution
GS03-13: Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis. The progression free survival improvement from ad...
Answer from: Medical Oncologist at Academic Institution
Updated analysis of the KATHERINE trial at a median follow up of 8.4 years that continues to show clinically and statistically significant benefits of adjuvant TDM1 as compared to trastuzumab in women with HER2-positive breast cancer who have residual disease after neo-adjuvant chemotherapy. The u...